Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846403 | 1.00 | DGAT1 (0.41) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846718 | 1.00 | DGAT1 (0.41) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846606 | 0.94 | RXFP1 (0.38) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846609 | 0.94 | RXFP1 (0.38) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846665 | 0.93 | L3MBTL1 (0.37) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846664 | 0.93 | L3MBTL1 (0.37) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846646 | 0.90 | DGAT1 (0.43) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846113 | 0.90 | KMT2A (0.48) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846111 | 0.90 | KMT2A (0.48) | DGAT1TSHRKMT2AMEN1POLB | |
| SCHEMBL24846684 | 0.90 | KMT2A (0.48) | DGAT1TSHRKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-114728919-A | MrgprX2 antagonists and uses thereof | 德米拉公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | DGAT1 811/4885TSHR 1201/4885KMT2A 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.